Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 62Leukemia, Myeloid, Acute 51Myelodysplastic Syndromes 39Leukemia 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Leukemia, Myelomonocytic, Chronic 34Leukemia, Lymphocytic, Chronic, B-Cell 26Blast Crisis 23Myeloproliferative Disorders 20Congenital Abnormalities 20Multiple Myeloma 17Anemia, Refractory 15Myelodysplastic-Myeloproliferative Diseases 14Hodgkin Disease 14Anemia 14Primary Myelofibrosis 13Lymphoma 13Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 13Lymphoma, Non-Hodgkin 12Leukemia, Myeloid, Chronic-Phase 12Thrombocytopenia 11Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 11Leukemia, Myeloid, Accelerated Phase 11Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Large B-Cell, Diffuse 10Hematologic Neoplasms 10Burkitt Lymphoma 10Lymphoma, Follicular 9Leukemia, Prolymphocytic 8

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Congenital Bone Marrow Failure Syndromes × Classical hematology × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡